Cvs Health Corp (CVS) Stock Price & Analysis
Cvs Health Corp (CVS) rose 0.80% to USD 107.74 as of July 25, 2026 at 01:12 UTC, according to Nexqual real-time market data.
CVS last closed at USD 106.89; the session ranged USD 106.98–108.39 on volume of 4,043,314 shares. Market capitalization is $137.47B, with a 52-week range of USD 58.99–110.68 (NYQ). Source: Nexqual, July 25, 2026 at 01:12 UTC.
Key Statistics (as of July 25, 2026 at 01:12 UTC)
| Price | USD 107.74 |
|---|---|
| Change | ▲ 0.80% (up) |
| Previous Close | USD 106.89 |
| Open | USD 107.65 |
| Day Range | USD 106.98 – 108.39 |
| 52-Week Range | USD 58.99 – 110.68 |
| Volume | 4,043,314 shares |
| Market Cap | $137.47B |
| Exchange | NYQ |
Technical Analysis (CVS)
Nexqual's technical model rates CVS "STRONG BUY" based on 5 bullish and 0 bearish signals across 125 daily candles, as of July 25, 2026 at 01:12 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 62.19 (neutral) |
| vs SMA50 | Above (USD 100.09) |
| MACD | 2.48 (positive) |
Analyst Ratings (CVS)
Wall Street analysts rate CVS "Strong Buy" based on 26 analysts, with a mean price target of USD 112.19 (range USD 79–148), per Nexqual as of July 25, 2026 at 01:12 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 26 |
| Mean Target | USD 112.19 |
| High Target | USD 148 |
| Low Target | USD 79 |
| Buy / Hold / Sell | 24 / 4 / 0 |
Earnings (CVS)
| Next Earnings Date | 2026-08-05 |
|---|---|
| EPS Estimate | USD 1.85 |
| Revenue Estimate | $100.09B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 2.57 vs est 2.21 ▲ beat |
| 2025-12-31 | USD 1.09 vs est 1 ▲ beat |
| 2025-09-30 | USD 1.6 vs est 1.36 ▲ beat |
| 2025-06-30 | USD 1.81 vs est 1.46 ▲ beat |
Source: Nexqual, July 25, 2026 at 01:12 UTC.
Financials & Fundamentals (CVS)
| Total Revenue | $405.62B |
|---|---|
| Revenue Growth (YoY) | +6.10% |
| Gross Margin | +13.39% |
| Operating Margin | +4.12% |
| Profit Margin | +0.72% |
| ROE | +3.75% |
| Debt / Equity | 100.91 |
| Current Ratio | 0.87 |
| Total Cash | $11.80B |
| Total Debt | $78.35B |
| Free Cash Flow | $5.20B |
Source: Nexqual, July 25, 2026 at 01:12 UTC.
Financial Health Score (CVS)
Nexqual rates Cvs Health Corp's overall financial health "Weak" across five dimensions, as of July 25, 2026 at 01:12 UTC.
| Growth | Solid — Revenue +8% YoY (annual) |
|---|---|
| Profitability | Weak — Gross margin 13%, operating 4% |
| Balance Sheet | Weak — $11.8B cash vs $78.3B debt |
| Cash Flow | Mixed — FCF $5.20B, slim 1.3% margin |
| Efficiency | Weak — ROE 4%, ROA 2.7% |
Ownership (CVS)
| Insider Ownership | +0.06% |
|---|---|
| Institutional Ownership | +90.14% |
| Shares Outstanding | 1.28B |
| Float | 1.27B |
| Short % of Float | +1.57% |
Source: Nexqual, July 25, 2026 at 01:12 UTC.
Leadership (CVS)
Cvs Health Corp is led by J. David Joyner CEBS (age 60), CEO, President & Chairman, per Nexqual as of July 25, 2026 at 01:12 UTC.
| CEO, President & Chairman | J. David Joyner CEBS (age 60) |
|---|---|
| Executive VP & CFO | Brian O. Newman (age 56) |
| Executive VP & Group President | Prem S. Shah Pharm.D (age 45) |
| Executive VP & President of Aetna | Steven Hale Nelson (age 66) |
Major Backers & Investors (CVS)
Notable institutional backers of Cvs Health Corp include Dodge & Cox Inc., Capital Group, WASHINGTON MUTUAL INVESTORS FUND, according to Nexqual as of July 25, 2026 at 01:12 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Dodge & Cox Inc. | 6.72% |
| Capital Group | 6.05% |
| WASHINGTON MUTUAL INVESTORS FUND | 2.49% |
| FMR, LLC | 2.45% |
| JPMorgan | 2.31% |
| Invesco | 1.97% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 15.14% |
| BlackRock | 11.18% |
| State Street | 5.86% |
| Geode Capital | 2.31% |
Source: Nexqual, July 25, 2026 at 01:12 UTC.
From Cvs Health Corp's Latest SEC 10-K Filing (filed 2026-02-10)
Key Strengths & Strategy (as disclosed to the SEC)
- We serve an estimated more than 37 million people through traditional, voluntary and consumer-directed health insurance products and related services, including expanding Medicare Advantage offerings and a leading standalone Medicare Part D prescription drug plan ("PDP").
- Retail Pharmacy Network Management Services The Company maintains a national network of approximately 63,000 retail pharmacies, consisting of approximately 34,500 chain pharmacies (which include CVS pharmacy locations) and approximately 28,500 independent pharmacies, in the U.S., including Puerto Rico, the District of Columbia, Guam and the U.S.
- During the year ended December 31, 2025, the Company performed more than 3.5 million IHEs. 9 While in the home, providers perform IHEs with the assistance of the Company's longitudinal patient records and proprietary clinical workflow software with its integrated device hub.
- The Health Engagement Engine ® technology and proprietary clinical algorithms help connect various parts of the enterprise and serve an essential role in cost management and health improvement, leveraging cloud-native technologies and practices.
Partnerships
- Under Duals contracts, the rate setting process is generally established by CMS in partnership with the state government agency participating in the demonstration project.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| TGT | Target Corporation | USD 136.78 | ▼ 0.83% |
| ABBV | AbbVie Inc. | USD 259.36 | ▲ 2.39% |
| BMY | Bristol-Myers Squibb Company | USD 62.09 | ▲ 2.19% |
| UNH | UnitedHealth Group Incorporated | USD 420.74 | ▼ 2.45% |
| ABT | Abbott Laboratories | USD 103.06 | ▲ 2.48% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 01:12 UTC. This page is informational and not investment advice.